Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selecta/JDRF Collaboration Seeks Vaccine To Prevent Or Treat Type 1 Diabetes

This article was originally published in The Pink Sheet Daily

Executive Summary

JDRF will provide milestone-based financial support toward preclinical proof of concept for a tolerogenic vaccine candidate.
Advertisement

Related Content

Deals of the Week: Sanofi/Selecta, Evotec/Probiodrug, Nestle/Chi-Med…
Sanofi And Selecta To Partner On Immunotherapies For Life-Threatening Allergies
Deals Of The Week: Upsher-Smith/Proximagen, Novo Nordisk/JDRF, Newron/NeuroNova
Novo Nordisk Partners With JDRF In Type 1 Diabetes Push
To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
No More Easy Vaccines, Merck's Gerberding Says In Call For Collaboration
No More Easy Vaccines, Merck's Gerberding Says In Call For Collaboration

Topics

Advertisement
UsernamePublicRestriction

Register

PS072482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel